| Trial ID: | L5191 |
| Source ID: | NCT00482079
|
| Associated Drug: |
Mk0431, Sitagliptin Phosphate / Duration Of Treatment: 21 Weeks
|
| Title: |
A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type II
|
| Interventions: |
DRUG: MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks|DRUG: Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks
|
| Outcome Measures: |
Primary: To asses the effectiveness of MK0431 compared to placebo, over 12 weeks | Secondary: To test the safety and tolerability of MK0431 in patients with type 2 diabetes
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
743
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2003-05-13
|
| Completion Date: |
2006-06-15
|
| Results First Posted: |
|
| Last Update Posted: |
2017-03-28
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00482079
|
